Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rx-TO-OTC SWITCHES AND OTC ANALGESIC CLAIMS ARE LIKELY TOPICS

This article was originally published in The Tan Sheet

Executive Summary

Rx-TO-OTC SWITCHES AND OTC ANALGESIC CLAIMS ARE LIKELY TOPICS for FDA's Nonprescription Drugs Advisory Committee in 1994, Committee Chairman Randy Juhl, PhD, University of Pittsburgh, told the Nonprescription Drug Manufacturers Association annual research and scientific conference in Washington, D.C. on Nov. 18. Juhl did not disclose which OTC switches would be considered by the panel. In addition to Syntex/P&G's naproxen sodium and SmithKline Beecham's cimetidine, which have already been reviewed by the committee, switch applications for Burroughs Wellcome's oral Zovirax (acyclovir) and Merck's Pepcid (famotidine) are currently pending at FDA. The question of whether all analgesic claims currently allowed under FDA's monograph for internal analgesics are appropriate for all OTC analgesic ingredients was an issue for the advisory committee in its review of Syntex/P&G's switch application for naproxen sodium and became a contributing factor in the panel's initial rejection of the switch at the June meeting. Juhl indicated that another probable item for the advisory committee's 1994 agenda is the subject of cold claims for OTC antihistamines, which he characterized as a "leftover" from late Rep. Ted Weiss' (D-N.Y.) FDA oversight. The issue was considered at an April 1992 hearing before Rep. Weiss' House Government Operations human resources and intergovernmental relations subcommittee. Rep. Edolphous Towns (D- N.Y.), who now chairs the subcommittee, has indicated an interest in revisiting the issue ("The Tan Sheet" Sept. 27, In Brief). Asked about the involvement of new drug review divisions in OTC issues, Oncology and Pulmonary Drug Products Division Director Gregory Burke, MD/PhD, said his division would be involved in the antihistamine issue when it goes before NDAC but that the "relative involvement would depend . . . on whether or not the issue comes as part of the monograph process or . . . as part of an NDA supplement." OTC Monograph Review Staff Director William Gilbertson, PharmD, noted in his presentation to NDMA on Nov. 19 that, in addition to the antihistamines issue, FDA plans to "definitely" bring pediatric dosing before the advisory committee "probably sometime in the spring." The Nonprescription Drugs Advisory Committee, Juhl noted, is tentatively set to meet four times in 1994: Feb. 16-17, May 18-19, July 28-29 and Dec. 1-2. In deference to OTC office Director Michael Weintraub, Juhl noted that the committee had a "relatively well laid out plan for the 1994 agenda but . . . we are going to have to start over again now that Dr. Weintraub is back in the saddle." Weintraub suffered a stroke on Sept. 12 and returned to his FDA post during the week of Nov. 15 ("The Tan Sheet" Sept. 20, p. 1).

You may also be interested in...



People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

UsernamePublicRestriction

Register

PS082179

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel